Taken together, the findings of this study and previous research suggest that the risk of FN and consequences thereof are considerable among patients receiving myelosuppressive chemotherapy for metastatic cancers who do not receive G-CSF prophylaxis. Here, CSF3 is linked to metastatic malignant neoplasm.